Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exenatide + Pioglitazone vs Basal-Bolus Insulin in T2DM
NCT02887625Unknown
- Start
- Feb 2015
- Primary completion
- May 2017
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of exenatide and pioglitazone in type 2 diabetes mellitus (T2DM). Status: unknown.
02
Drugs
exenatidepioglitazone
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02887625.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02887625.